Background {#Sec1}
==========

Delirium is a common problem in hospitalized elderly individuals; it is defined as an acute onset of impaired cognitive functions, disturbance in attention and awareness that is not due to a pre-existing, established, or evolving neurocognitive disorder. Post-operative delirium (POD) usually emerges on post-operative day 1 to 3, after a lucid interval after emergence from anaesthesia \[[@CR1]\]. The distinction between emergence agitation, post- anaesthesia care unit (PACU) delirium and POD are difficult to distinguish, their definitions have been based on review of literature and expert opinion \[[@CR2]\]. Emergence agitation has been defined as agitation after discontinuation of inhaled anaesthetics, while PACU delirium has been defined as positive delirium signs after 30 min stay in PACU until discharge from PACU (delirium signs upon arrival in PACU may be considered continuation of emergence from general anaesthesia) \[[@CR2]\]. PACU delirium may be a subset of POD and patients who experience PACU delirium are reported to have higher risk of POD \[[@CR3]\].

The aetiology of POD is poorly understood but is probably due to the presence of underlying mechanisms of immune activation, oxidative stress and neurotransmitter imbalances in predisposed individuals \[[@CR4]\]. Serious short and long-term adverse outcomes include persistent functional decline, prolonged hospital stay, higher morbidity and mortality, and increased health care costs.

Many delirium risk prediction models have low specificity \[[@CR5]\]. There is increasing interest in investigating the pathogenesis of POD as reflected by the high number of studies examining various biomarkers. Investigating possible biomarkers to identify high-risk patients may advance understanding about the pathophysiology of delirium. This systematic review aims to summarize the current evidence with respect to biomarkers and imaging tests that may predict POD in non-cardiac surgery patients**.**

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

A systematic search of the literature was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) guidelines, Fig. [1](#Fig1){ref-type="fig"}. A comprehensive electronic search with the assistance of an expert medical librarian was conducted. The following databases were searched; MEDLINE (1946 to January 2018), Medline In-Process (up to January 2018), EMBASE (1947 to January 2018), Cochrane Central Register of Controlled Trials (up to December 2017), Cochrane Database of Systematic Reviews (2005 to January 2018), PsychINFO (1806 to January 2018), CINAHL, PubMed (up to January 2018) and ClinicalTrials. Gov (up to January 2018). We included randomized and non-randomized controlled trials, prospective and retrospective observational studies, and cross-sectional studies.Fig. 1Flow diagram of study

The search included a combination of the following MESH keywords "emergence delirium", "cognitive disorders", "cognition", "acute confusion", "delirium", "hallucination", "dementia", "mental", "post-anaesthesia", "symptom assessment", "algorithm surveys and questionnaires", "assess", "audit", "checklist", "focus group", "patient reported outcome measures", "interview", "instrument", "QoL", "screening", "survey", "pre-operative care", "pre-procedure", "post-operative", "evaluation", "validation", "DSM" and "Diagnostic and Statistical Manual of Mental disorders". The detailed search strategy is provided in Additional file [1](#MOESM1){ref-type="media"}.

Study selection and data extraction {#Sec4}
-----------------------------------

Potentially eligible studies were reviewed independently by two reviewers (EL and GH). Title review and abstracts were screened to determine if the inclusion/exclusion criteria were fulfilled. Any disagreements or queries were resolved by consulting the senior author (JW). Full text review of all included studies was conducted independently by the 3 reviewers (EL, GH and FA). Studies reporting the following were included: 1) Pre-operative biomarker testing for predicting POD, 2) imaging techniques to predict POD and 3) POD diagnosed by physician's assessment or a validated tool. Exclusion criteria were paediatric studies, animal studies, non-English publications, intracranial or cardiac surgery, abstracts and studies that assessed emergence agitation as POD in their analysis or used non-validated tools for delirium assessment. We also excluded studies that examined post-operative biomarkers. Information extracted from each study were: first author and year of publication, sample size, mean age for POD and non-POD groups, country, type of surgery, elective or emergent, pre-operative dementia, pre-operative investigation for delirium, method of diagnosis for POD and day of POD diagnosis.

Assessment of methodological quality {#Sec5}
------------------------------------

Each study was evaluated for risk of bias in 6 study domains using the Quality in Prognostic Studies (QUIPS) tool, (Additional file [2](#MOESM2){ref-type="media"}: Table S1) \[[@CR6]\]. The QUIPS tool has been used widely for methodological quality in systematic reviews of risk prediction models. It assesses bias in prognostic factor studies; and rates 6 bias domains: 1) study participation (definition and description of the study subjects); 2) study attrition (study loss to follow-up); 3) prognostic factor measurement (quantitatively measured predictors of interest); 4) confounding measurement and handling; 5) outcome measurement (quantitatively measured outcome of interest) and; 6) statistical analysis (calibration and discrimination) as having high, moderate or low risk of bias \[[@CR4]\]. Two reviewers (EL and GH) evaluated each study independently and discrepancies were resolved by analysing the weight of factors of bias described in the studies by a third author (FA).

Results {#Sec6}
=======

The initial electronic database search retrieved 6214 potential studies with 3 additional studies retrieved from citations (Fig. [1](#Fig1){ref-type="fig"}). After removal of 2679 duplicates and reviewing the titles and abstracts, 34 studies were included for final full text review. Since the predictive tests and the manner of results reporting was heterogeneous \[e.g. odds ratio (OR) vs. *P*-values only\], and the number of studies for each specific test was low, we did not perform a quantitative analysis and limited our review to qualitative evaluation.

Description of included studies and indices {#Sec7}
-------------------------------------------

POD assessment was performed using the Delirium Observation Screening Scale (DOSS) \[[@CR7]\] Confusion Assessment Method (CAM) \[[@CR8]--[@CR36]\] or CAM-ICU \[[@CR13], [@CR24], [@CR36]\], Delirium Rating Scale (DRS) \[[@CR9], [@CR15], [@CR31], [@CR37]\], Diagnostic and Statistical Manual of Mental Disorders (IV) \[DSM IV\] \[[@CR7], [@CR14], [@CR36]--[@CR39]\], or validated chart review \[[@CR10], [@CR21], [@CR24], [@CR34], [@CR35]\]. Most studies assessed POD from the day of surgery, three studies assessed POD from post-operative day 2 onwards \[[@CR8], [@CR9], [@CR15]\], and 6 studies did not specify the time of POD assessment \[[@CR7], [@CR23], [@CR35]--[@CR37], [@CR40]\]. In studies which assessed delirium on the day of surgery, none mentioned whether they included PACU delirium or distinguished between emergence agitation or POD.

Study characteristics {#Sec8}
---------------------

The main characteristics of the studies are shown in Table [1](#Tab1){ref-type="table"}; serum biomarkers and Table [2](#Tab2){ref-type="table"}; imaging tests. All were prospective cohort studies apart from one randomised controlled trial \[[@CR41]\]. The 34 studies included data from 4424 patients. Nineteen studies described pre-operative serum biomarker tests \[[@CR8], [@CR10], [@CR12]--[@CR25], [@CR37], [@CR38], [@CR41]\], 10 described CSF biomarker tests \[[@CR7], [@CR9], [@CR11], [@CR26]--[@CR33]\] and 5 described imaging tests \[[@CR34]--[@CR36], [@CR40], [@CR41]\]. Four studies investigated several different biomarkers \[[@CR9], [@CR11], [@CR14], [@CR17]\].Table 1Summary of studies: Pre-operative serum testsAuthor, Year, CountryStudy designnCut-off ageType of surgeryIncluded patients with dementia or cognitive impairmentMultivariate regression analysis performedPre-operative testsPOD assessment, Days post-surgery assessmentPOD- mean age, % femaleNo POD -- mean age, % femaleConclusionPre-op Test Predictive of PODBiomarkersCapri, 2014, Italy \[[@CR8]\]PC74 (37 w/ POD, 37 w/o POD)\> 65Any elective and emergency surgery, excluding cardiacNoYesPlasma cytokine concentrations (TNF-a, IL-1b, IL-2, IL-6, IL-8, and IL-10)CAM and DRS, D1,2,3 and 679.2 yr., 45.9%76.4 yr., 54%High serum IL-6 (\> 9 pg/mL) independently predicts POD.\
OR 4.9, \[1.6--14.63; *P* \< 0.0005\].YesWesthoff, 2013, Netherlands \[[@CR9]\]PC61\> 75Emergency hip fractureYesMA logistic regression analysis not performed but no significant correlation was found between age, cognitive function and levels of CSF cytokines.42 CSF and serum cytokines and chemokinesCAM, DRS-R- 98, D1--582.9 yr., 69.9%84.6 yr., 68.4%Pre-op CSF Fms-like tyrosine kinase-3, IL-1r antagonist and IL-6. Pre-op serum IL-6 was significantly higher in patients with POD. Median levels in POD vs .no POD: 48.13 vs 23.16, *P* = 0.021.YesDillon, 2017, Israel and UK \[[@CR10]\]PC566, Sub cohort from SAGE\> 70, Pooled cohort (combined match pairs)Elective major non-cardiacNoConditional logistic regression and sensitivity analysis performed.Serum CRPCAM and validated chart review, POD = D1--277.6 yr., 56%77.2 yr., 56%Elevated pre-op CRP associated with POD (pre-op median paired difference with controlled subjects of 1.97 mg/L, P = 0.02).YesNeerland, 2016, Norway & UK \[[@CR11]\]PC151 Oslo 99, Edinburgh 52\> 60Emergency hip fractureYesNoSerum and CSF CRP, IL-6 and soluble IL-6 receptorCAM\
O: D1--5,\
E: D1--4, 7, 10,1485 yr., 70%83 yr., 80%Significantly high CSF levels of CRP in POD vs. no-POD, median 0.05mcg/mL vs. 0.01mcg/mLYesVasunilashorn, 2017, USA \[[@CR12]\]PC560 (sub cohort from SAGE)\
POD = 25% of participants\> 70Major non-cardiac surgeryNoNoSerum CRPCAM, D1 until discharge77.7 + − 5.0 yr., 60%76.5 + −  5.2 yr., 58%Subjects with pre-op CRP of ≥3 mg/L had a 1.5 greater risk of delirium than subjects with CRP; 4 more delirium days (*P* \< 0.001) and 1.4 times greater risk of prolonged LOS.YesXiang, 2017, China \[[@CR13]\]PC160\
POD = 39(24.4%)\> 65Laparoscopic surgery for colon carcinomaNoYesSerum CRPCAM-ICU D1--3 and 772.2 + −  5.8 yr.,\
41%69.4 + −  7.1 yr.,\
39.7%Pre-op CRP level: independent predictor of POD. POD vs. no POD CRP levels; 3.8 vs. 2.4 mg/L (OR: 5.87; 95% CI 2.22--11.4, *P* = 0.018).YesBohner, 2003, Germany \[[@CR38]\]PC153N/SElective Vascular surgeryNoNo. Only Univariate analysis performed.Pre-op: CRP, White cell count, platelets, LFTs, Creatinine, Urea, coagulation, Intra-op: BP, BG, glucoseDSM IV criteria,\
DRS \> 12, D1--763.7 + − 10.3 yr.,68.3 + −  8.5 yr.,Pre-op CRP significantly higher in POD vs. no POD; 3.4 vs. 1.7 mg/dL, *P* = 0.03. AT III (98% vs. 106%, *p* = 0.02), lower Hb 13.7 vs. 14.3 g/dL, *P* = 0.02).YesLemstra, 2008, Netherlands \[[@CR14]\]PC68\> 70Elective hip replacementYesNo. Patients were matched for age, severe illness and MMSE score \< 24 using a statistical analysis.Serum CRP, IL-6, IGF-1CAM and DSM-IV daily80 yr., 55.6%78.5 yr., 74%No difference between POD vs. no POD levels: CRP = 5.3 vs. 3 mgL^− 1^, *P* = 0.523; IL-6 = 3.6 vs. 3.0 pgmL^− 1^, *P* = 0.121; IGF-1 = 14.4 vs. 12.9 nmolL ^− 1^, *P* = 0.675.NoShen, 2016, China \[[@CR15]\]PC140\> 65Elective open GI tumour resectionNoYesSerum IGF-1CAM, DRS-R98. D2,373.8 yr., 52.8%68.8 yr., 58.7%Significantly low serum IGF-1 (POD vs. no-POD, 50.4 vs. 67 ng/mL), OR 2.52 (1.19--5.43).Yes.\
Cut-off level 52.94 ng/ml, sensitivity of 80.8%, specificity of 80.6%.Yen, 2016, USA \[[@CR37]\]PC98\> 65Elective knee replacementNoYesSerum IGF-1DSM-IV, DRS-R9872.5 yr., 59%73.7 yr., 50%No association. Median levels in POD vs. no POD = 62.6 vs. 65.9 ng/mL, *P* = 0.141.NoCerejeira, 2011, Portugal \[[@CR16]\]PC101\> 60Elective total hip replacementNoNoPlasma AChE and BuChE activityCAM, D1,2,373.7 yr., 60%72.7 yr., 46%AChE and BuChE 24 and 32% lower in patients with vs. without POD, respectively. Pre-operative differences between the two groups were controlled.YesCerejeira, 2012, Portugal \[[@CR17]\]PC101\> 60Elective total hip replacementNoNoPlasma AChE and BuChE and inflammatory mediator levels (CRP, IL-1b, and TNF-a)CAM, D1,2,373.6 yr., 60%72.7 yr., 45.3%Low baseline plasma cholinesterase activity associated with POD and positively correlates with high CRP, IL-6 and Pro-inflammatory/ Anti-inflammatory ratio.YesChen, 2014, China \[[@CR18]\]PC186\> 65Emergency hip fractureNoYesPlasma leptinCAM, D1,2,3,7 and 1 month80.1 yr., 72%74.7 yr., 77%Plasma leptin level is significantly lower in POD vs. no-POD, 4 vs. 7.5 ngmL^− 1^, *P* \< 0.001). Hypoleptinaemia is an independent predictor of POD \[OR 0.385, CI 0.28--0.517\].Yes. Sensitivity 72.2%, Specificity 91.7%Cunningham, 2017, UK \[[@CR19]\]PC315\> 65Elective hip or knee replacementNoYesSerum ApoE4 allele carriage and neuropsychological testsCAM, D1,2,376.9 yr., 65%74 yr., 27.1%ApoE4 genotype is not associated with POD.NoLeung, 2007, USA \[[@CR20]\]PC190\> 65Elective major non-cardiacNoYesSerum apolipoprotein (APOE) genotypeCAM, D1--274.2 yr., NR72.3 yr., NRPresence of at least one copy of APOE e4 allele is associated with increased risk of POD that persists 2 days post-op.\
(OR 3.64, 95% CI 1.51--8.77).YesVasunilashorn, 2015, USA \[[@CR21]\]PC557\> 70Any Elective major non-cardiacNoSensitivity analyses performed to test if dementia has any influence on association between ApoE and POD.Serum Apolipoprotein E: e2, e4 carrier vs non-carrier and three category ApoE genotypes (e3e3, e3e4, e4e4, e2e2, e3e2)CAM and validated chart review dailyApoE genotype has no association with incidence, severity or duration of POD, RR for E4 = 1.0, CI 0.7--1.NoTorbergsen, 2015, Norway & Scotland \[[@CR22]\]PC115NREmergency hip fractureNoYesSerum vitamin levels (Vitamin A, B1, B6, vitamin B12, Folic acid, vitamin C, D, K)CAM, D1--584.8 yr., 71%80.6 yr., 79%Vitamin D deficiency (\< 50 nmol/L) was independent predictor of POD. (Mean Vitamin D in POD vs. no-POD, 41 vs. 52 nmolL^−1^, P = 0.05).YesScholtens, 2017, Netherlands \[[@CR23]\]PC144\> 65Emergency hip fractureNoNoMorning plasma melatoninCAM85.5 yr., 75%82.5 yr., 69%Morning melatonin not associated with POD (*p* = 0.35)NoScholtens, 2016, Netherlands \[[@CR7]\]PC60\> 65Emergency hip fractureYesNo but confounders (age and cognitive impairment) analysed and did not show any difference in CSF melatonin levels.CSF melatoninDelirium Observation Screening Scale, and DSM-IV, NS86.4 yr., 83.3%83.4 yr., 66%Pre-operative CSF melatonin did not differ between POD and no-POD groups. No MA performedNoWyrobek, 2017, USA \[[@CR24]\]PC77\> 70Major Spine surgery\
Median age = 75 years, 47% were femaleNoYesIntra-op serum brain derived neurotrophic factor (BDNF)CAM, D1--4\
CAM-ICU\
Validated chart reviewNRNRSubjects with POD vs no. without POD had a greater percentage of BDNF decline from baseline, median 75% (IQR 51--82) vs. 50% (IQR 14--79, P = 0.03).YesZhang, 2017, China \[[@CR25]\]PC700\
111 (15.9%)\> 65Elective non -cardiac surgery who were admitted to ICUNoYesPre-op serum albumin levelsCAM-ICU D1--776.2 + −7.8 yr., 47.7%74.0 + − 6.6 yr.,\
38%Pre-op severe hypoalbuminemia (\< 30.0 g/L) was associated with increased risk of POD (OR 2.727, 95% CI 1.28--5.797, *P* = 0.009) .YesHall, 2016, Norway and Scotland \[[@CR26]\]PC139\
(Oslo- 85, Edinburgh- 54)Oslo- \> 60,\
Edin \> 61Emergency hip fractureYesYesSerum and CSF neopterin.CAM, D1--585 yr., 70%82 yr., 77%Higher pre-op CSF neopterin in POD vs. no-POD. (Median 29.6 vs 24.7 nmolL^− 1^, *P* = 0.003).YesHov, 2016, Norway \[[@CR27]\]PC120NREmergency hip fractureYesNoSerum and CSF albumin. q-albumin (ratio of CSF albumin to serum albumin)CAM, D1--585 yr., 70%83 yr., 83%CSF barrier dysfunction (q-albumin\> 10.2). Significant difference in POD vs. no POD group, n = 11 (16% vs 0%, P = 0.022).YesWatne, 2014, Norway \[[@CR28]\]PC151\
Oslo = 99\
Edin = 52Oslo- NR, Edin \> 60, 84.Emergency hip fractureNoYesSerum and CSF anticholinergic activityCAM D1--5Oslo: 75%\
Edin: 60%Oslo 72%, Edin: 75%Serum or CSF anticholinergic activity is not an important mechanism in POD.NoWatne, 2016, Norway \[[@CR29]\]PC77\> 70Emergency hip fractureNoYesSerum and CSF monoamine precursorsCAM D1--586 yr., 70%84 yr., 61%Higher CSF monoamine precursors (tryptophan, tyrosine, phenylalanine, methionine, 5-HIAA) in delirium patients suggests high monoaminergic activity in CNS during delirium.YesHov 2017, Norway \[[@CR30]\]PCHip fracture = 98\
Elective surgery = 50\> 70Hip fracture and elective surgery (gynae, urology or orthopaedicNoNoSerum and CSF S100B and phosphorylated tau (P-tau) concentrationCAM D1--5Prevalent delirium- 85 yr., 75%, Incident delirium- 88 yr., 56%84 yr., 78%Significant difference in CSF S100B in patients with vs. without incident delirium (1.38 vs. 1.08 μgrams/L, P = 0.013).YesHall, 2013, Scotland \[[@CR31]\]PC45\> 60Emergency hip fractureYesNoSerum and CSF S100BCAM and DRS-R98, D1--4,7,10--1481.3 yr., 63%78.9 yr., 73%No significant difference in log10 CSF S100B in POD vs no-POD during the 2-week period (mean: −0.239 vs −0.308 respectively; student's t-test t = 1.25, df = 43, *P* = 0.218).NoWesthoff, 2015, Netherlands \[[@CR32]\]PC53\> 75, mean age 83.1, 67.9%Emergency hip fractureYesYesCSF proteins (low complement factor C3, fibulin-1, 1-beta-1,3 N-acetylglucosaminyl-transferase in POD, high neural cell adhesion molecule-2, fibrinogen, zinc-α-2-glycoproteinandhaptoglobin level in POD)CAM, D1--5NRNRDiscrepencies of results between proteomic ccohort and validation cohort.NoWitlox, 2011, Netherlands \[[@CR33]\]PC76\> 75Emergency hip fractureYesYesCSF levels of senile plaques B amyloid and neurofibrillary tangles (Ptau)CAM, D1--584.7 yr., 67%82.4 yr., 67%CSF markers for plaque and tangle formation are not strongly associated with POD.No*PC* Prospective cohort, *n* number, *POD* Post-operative delirium, *TNF* tumour necrosis factor, *IL* interleukin, *CAM* confusion assessment method, *DRS* delirium rating scale, *D1* day 1, *AChE* acetylcholinesterase, *BChE* butylcholinesterase, *CRP* c-reactive protein, *MMSE* mini mental state examination, *SAGE* Successful Ageing after Elective Surgery, *NR* not recorded, *AT III* angiotensin III, *Hb* hemoglobin, *5-HIAA* 5-hydroxyindoleacetic acid, *GI* gastrointestinal, *CSF* cerebral spinal fluid, *CAM-S* Confusion Assessment Method- Short Form, *DSM-IV* Diagnostic and Statistical Manual 4th, *IGF* Insulin Like Growth Factor, *PACU* post-anaesthesia care unit, *GA* general anaesthesia, *ICU* intensive care unit, *GABA* gamma amino butyric acid, *Fms* Fat Mobilising substance, *OR* odds ratio, *CBF* cerebral blood flow, *MA* multivariate analysisTable 2Summary of studies: imaging testsAuthor, Year, CountryStudy designnCut-off ageType of surgeryIncluded patients with dementia or cognitive impairmentMultivariate regression analysis performedPre-operative testsPOD assessment, Days post-surgery assessmentPOD- mean age, % femaleNo POD -- mean age, % femaleConclusionPre-op Test Predictive of PODImaging Cavallari, 2016, USA \[[@CR34]\]PC136\> 70,Elective non-cardiacNoNo but no significant difference were found between subjects (age, gender, vascular comorbidities)MRI DTI of brainCAM and validated chart review, dailyNR, 69%NR, 56%Significant association of DTI abnormalities in a variety of brain regions with POD. Mean differences in DTI indices between POD and non-POD = 3--8%, *P* \< 0.05.Yes Hshieh, 2017, USA \[[@CR35]\]PC146\> 70Elective major non-cardiacNoNoMRI of global and regional cerebral blood flowCAM and validated chart reviewNR, 69%NR, 56%No significant association between MRI of cerebral blood flow with POD in both adjusted and unadjusted analyses.No Miller, 2017, USA \[[@CR40]\]PC142\> 65Elective general surgeryNoYesCT of total psoas areaRetrospective medical record reviewNRNRLow total psoas area is associated with POD (OR 3.12, 95% CI = 1.02--9.56, *P* = 0.046).Yes Root 2013, USA \[[@CR41]\]RC48NRAnatomic lung resection for non-small cell carcinomaNoNoMRI -- WMHB and CADoctors, psychiatry and nurses detect confusion, disorientation, hyperactivity. D1--473.39 yrs., 56.5%73.63 yrs., 54%WMHB higher in POD vs no POD group (mean 0.01% vs 0.005% of total intracranial volume) *p* = 0.017.Yes Racine 2017, USA \[[@CR36]\]PC145 (subset of SAGES)\> 70Elective major non-cardiacNoYesMRI of cortical thickness in Alzheimer's Disease signature regionsCAM, validated chart review77 +/− 4.3 yrs., 69%76 +/− 4.6 yrs., 58%Alzheimers' Disease signature cortical thickness did not predict POD (OR = 1.15, 95% CI \[0.8, 1.6\].No*PC* prospective cohort, *RC* retrospective cohort, *n* number, *POD* post-operative delirium, *NR* not recorded, *CT* computed tomography, *OR* odds ratio, *CI* confidence interval, *p* probability, *RC* randomized controlled, *MRI* magnetic resonance imaging, *DTI* diffusion tensor imaging, *CAM* Confusion Assessment method, *D1--4* Day 1--4, *SAGES* Successful Ageing After Elective Surgery, *yrs.* years, *WMHB* white matter hyper-intensity burden, *CA* cerebral atrophy, *MA* Multivariate analysis

The studies were conducted in the United States, Europe and Asia. During data analysis, it was noted that several studies used the same patient population but examined different biomarkers. Specifically, 2 studies by Carejeira and colleagues \[[@CR16], [@CR17]\], and 6 studies used a subset from the Successful Aging after Elective Surgery (SAGE) study \[[@CR10], [@CR12], [@CR21], [@CR34]--[@CR36]\]. The SAGE study was a prospective observational study evaluating the risk factors and long-term outcomes of delirium in 566 patients older than 70 years undergoing major non-cardiac surgery \[[@CR39]\].

Five studies were major elective orthopaedic surgery \[[@CR14], [@CR16], [@CR17], [@CR19], [@CR37]\], 14 emergency hip fracture surgery \[[@CR7], [@CR9], [@CR11], [@CR18], [@CR22], [@CR23], [@CR26]--[@CR29], [@CR31]--[@CR33]\], 10 major non-cardiac surgery \[[@CR8], [@CR10], [@CR12], [@CR20], [@CR21], [@CR25], [@CR30], [@CR34]--[@CR36]\], 3 general surgery \[[@CR13], [@CR15], [@CR40]\], 1 spine surgery \[[@CR24]\], 1 vascular surgery \[[@CR38]\] and 1 lung resection surgery \[[@CR41]\]. All studies that examined CSF biomarkers involved emergency hip fracture patients. Most studies tested their biomarkers pre-operatively apart from 10 studies which tested their biomarkers in the pre-operative and post-operative period \[[@CR10], [@CR12], [@CR13], [@CR17]\].

Risk of Bias {#Sec9}
------------

In general, risk of bias of all studies were low (Table [3](#Tab3){ref-type="table"}). For the domain 'study participation', 6/34 (17.6%) had a moderate risk and 1 study had a high risk of bias. Confounding measurement was found to have moderate risk of bias in 23.5% (*n* = 8) of the studies. Five studies had moderate bias for attrition measurement and the main reasons were low numbers of eligible participants \[[@CR18], [@CR31]--[@CR33]\]. Prognosis factor measurement and statistical analysis domains had low bias for all studies due to clear descriptions of valid prognostic factor measurements, and well-chosen statistical models that assessed the data in a non-selective manner respectively.Table 3Summary of risk of bias assessmentDomainsLow risk n (%)Medium riskHigh riskStudy participation27 (79.4%)6 (17.6%)1 (2.9%)Study attrition29 (85.3%)5 (14.7%)0 (0)Prognosis factor measurement34 (100%)0 (0)0 (0)Outcome measurement33 (97.1%)0 (0)1 (2.9%)Confounding measurement26 (76.5%)8 (23.5%)0 (0)Statistical analysis34 (100%)0 (0)0 (0)

Biomarkers {#Sec10}
----------

### Inflammatory mediators {#Sec11}

Ageing is associated with chronically low levels of inflammation \[[@CR8]\]. The association of each biomarker with POD is summarized in Table [4](#Tab4){ref-type="table"}.Table 4Summary of association of biomarkers and imaging tests with post-operative deliriumBiomarkersNumber of studies with positive association with post-operative deliriumReferencesNumber of studies without an association with post-operative deliriumReferencesIL-626, 7112CRP58, 9, 10, 11,,34112IGF-1113212,35Angiontensin III134Hemoglobin134Reduced Cholinesterase activity214, 150Brain derived neurotrophic factor (BDNF)1220Anticholinergic activity0126Serum leptin116APO E 4 genotype118217, 19Hypovitaminsosis (Vitamin D deficiency)1200Melatonin025, 21Hypoalbuminemia1230Neopterin1240Monoamine precursor1270CSF Acute phase proteins0130S100B128129Plaques/ tangles0131CSF barrier dysfunction1250Magnetic Resonance Imaging232, 40233, 41Computed Tomography Imaging1380*IL-6* interleukin-6, *CRP* C-reactive protein, *IGF-1* insulin growth factor-1, *APO-E* alolipoprotein-E, *GABA* gamma aminobutyric acid

### Il-6 {#Sec12}

Two studies showed elevated pre-operative serum IL-6 \[[@CR8], [@CR9]\], and 1 study did not find any association \[[@CR14]\]. One study described their median IL-6 level in the POD group vs. non-POD group was 9 pgmL^− 1^ vs. 3.4 pgmL^− 1^ \[[@CR8]\]. The other study showed no difference in CSF IL-6, however found significant difference in serum levels; (POD vs. non-POD: 48.1 vs. 23.1 pgmL^− 1^) \[[@CR9]\]. The reason for the significant discrepancy in median absolute values between the two studies is not clear. However, the main difference between the two studies which may account for the different IL-6 levels was the use of pre-operative anti-inflammatory drugs; whereby the study which excluded its use reported higher IL-6 levels \[[@CR9]\], while the study which reported lower IL-6 levels clearly indicated its main limitation was the absence of information on use of pre-operative anti-inflammatory drugs \[[@CR8]\].

### CRP {#Sec13}

An association between raised CRP and POD was shown in 5 studies \[[@CR10]--[@CR13], [@CR38]\], and 1 study \[[@CR14]\] found no association. Vasinulashorn et al. \[[@CR12]\] used a cut-off level for raised CRP as \> 3 mgL^− 1^; where levels above this showed 1.5 times greater risk of developing delirium. Dillon et al. \[[@CR10]\] showed higher CRP levels in POD; measured difference between POD and non-POD groups (median difference of 1.97 mgL^-1,^ *P* = 0.02). One study in general surgical patients showed higher levels in POD; (POD vs no POD, 3.8 mgL^− 1^ vs. 2.4 mgL^− 1^) \[[@CR13]\], as well as another study in vascular patients (POD vs no POD; 3.4 vs. 1.7 mgL^− 1^) \[[@CR38]\]. Neerland et al. \[[@CR11]\] compared CSF CRP levels between the two groups; (POD vs. no POD, 0.05 vs. 0.01 mcgmL^-1)^. Based on these studies, a serum level cut-off of CRP \> 3 mg/L is reasonable for predicting POD. The one study which found no association was small and may have been underpowered to show a difference \[[@CR14]\]. This study also included patients with baseline cognitive impairment whereas the four studies excluded patients with cognitive impairment.

### IGF-1 {#Sec14}

IGF-1 is a peptide growth hormone released mainly by the liver. It is neuroprotective; promoting neuronal survival and prevents oxidative stress by inhibiting cytokines. A reduced level may predispose the brain to cytotoxic effects of cytokines \[[@CR15]\]. Low serum IGF-1 was significantly associated with POD in 1 study \[[@CR15]\], however 2 studies \[[@CR14], [@CR37]\] found no association. Only 1 study evaluated the relationship between IGF-1 levels and severity of delirium, and did not find a significant association \[[@CR37]\].

### Neopterin {#Sec15}

CSF neopterin is a marker of intrathecal immune activation and reflects CNS inflammation. It is synthesized upon stimulation of interferon gamma produced by activated T cells \[[@CR42]\]. Increased neopterin levels were found in patients with delirium, even after adjustment for inflammatory state \[[@CR43]\]. Significantly higher levels of pre-operative CSF neopterin were found in the POD group compared to non-POD group (29.6 vs 24.7 nmolL^− 1^, *P* = 0.03), even when participants with infection and malignant disease were excluded \[[@CR26]\].

### ApoE4 genotype {#Sec16}

Apolipoprotein E (ApoE) is a component of plasma lipoprotein involved in central acetylcholine synthesis and maintenance of myelin and neuronal membranes during development or after injury. There are three isoforms of ApoE: E2, E3 and E4. The ApoE4 allele is most vulnerable to degradation compared to other isoforms, hence it carries the main genetic risk factor for late onset Alzheimer's disease and is associated with greater risk of amyloid plaque deposition and cerebral amyloid angiopathy \[[@CR44]\]. One study reported that the presence of one copy of the e4 allele increased risk of POD that persisted for 2 days post-operatively (28.3% vs. 11.1%; *P* = 0.005) \[[@CR20]\], however two more recent studies reported no association \[[@CR19], [@CR21]\]. Interestingly, a recent systematic review of ApoE4 association with delirium concluded no significant association \[[@CR45]\].

### Anticholinergic activity {#Sec17}

Cholinergic deficiency in the brain is known to play a role in delirium. Acetylcholine degradation not only causes cognitive dysfunction, but also induces inflammation in the central and peripheral nervous systems \[[@CR46]\]. Impairment of its receptors might lead to cholinergic deficiency and delirium development \[[@CR47]\]. One study investigated serum and CSF anticholinergic activity (AA) using muscarinic radio receptor bioassay, and expressed AA in terms of atropine equivalents (pmol/mL). It did not show an association with POD in the two centres in either serum AA in Oslo and in Edinburgh or CSF AA in Oslo and in Edinburgh \[[@CR28]\].

### Cholinesterases {#Sec18}

Acetylcholinesterase and butylcholinesterases (AChE and BuChE) metabolise acetylcholine which results in a lack of cholinergic transmission; a proposed central mechanism of delirium \[[@CR48]\]. Cerejeira et al. reported a significantly lower plasma AchE and BuChE of 24 and 32% respectively in the POD vs. non-POD group \[[@CR16]\] and positive correlation between baseline plasma cholinesterase activity and pro-inflammatory/anti-inflammatory ratio \[P/A, P/A = (IL 1B + TNF-A + IL-6 + IL-8)/ IL-10\] with POD \[[@CR17]\]. However, when assessing each mediator individually, no differences were observed between the 2 groups in the latter study \[[@CR17]\]. The authors concluded that isolated levels of cytokines in the bloodstream do not necessarily capture the complex homeostatic dysfunction occurring during a delirium episode, and P/A ratios might be a more valuable index of cytokine response during a delirium episode \[[@CR17]\].

### Blood brain barrier dysfunction {#Sec19}

Blood brain barrier dysfunction has been described in dementia \[[@CR49]\], but not many studies have described its role in delirium. Pre-operative CSF and serum albumin ratio as a marker of blood brain barrier (BBB) dysfunction (q albumin = ratio of CSF albumin to serum albumin, q \> 10 = CSF barrier dysfunction) has been examined in one study. A significant difference was found in q albumin between the POD and the non-POD group after hip fracture surgery \[*n* = 11 (16% vs. 0%), *P* = 0.022\] \[[@CR27]\].

### Melatonin {#Sec20}

Melatonin is responsible for regulation of circadian rhythm and sleep-wake cycle; the latter being a core feature in delirium. It also inhibits the aggregation of the amyloid beta protein into neurotoxic micro-aggregates responsible for the neurofibrillary tangles in Alzheimer's disease and prevents hyperphosphorylation of the tau protein \[[@CR50]\]. Two studies however failed to show an association between pre-operative melatonin levels and POD \[[@CR10], [@CR23]\].

### Monoamine precursors {#Sec21}

Monoamines such as dopamine, noradrenaline and serotonin have important roles in attention and cognition \[[@CR51]\]. The rate of monoamine synthesis in the brain is determined by monoamine precursors (tryptophan, tyrosine and phenylalanine). One study examined the association between POD and amino acids and/or monoamine metabolites (5-hydroxyindoleacetic acid; 5-HIAA) levels in the CSF in patients with and without pre-existing dementia. Significantly higher CSF levels of tryptophan, 0.8 vs. 1.1 μmolL^− 1^, *P* = 0.042; tyrosine, 5 vs. 8 μ molL^− 1^, *P* = 0.028; phenylalanine, 9 vs. 14 μ molL^− 1^, *P* = 0.014; methionine, 3 vs. 4 μmolL^− 1^, *P* = 0.03 and monoamine metabolite 5-HIAA, 138 vs. 170 nmolL^− 1^, *P* = 0.048 were found in the POD vs. the non-POD group after hip fracture surgery \[[@CR29]\]. These findings were found in patients without pre-existing dementia. When patients with and without dementia were analysed together, only CSF methionine and serum taurine were significantly different between the POD and non-POD group. The study suggested that increased monoaminergic activity is associated with delirium in hip fracture patients.

### CSF protein {#Sec22}

Acute phase proteins (complement c3, fibrinogen and haptoglobin) may be associated with the inflammatory process in delirium \[[@CR52]\]. Complement factor C3, contactin-1, fibulin-1 and I-beta-1,3-N-acetylglucosaminyl transferase were significantly lower, while neural cell adhesion molecule-2, fibrinogen, zinc-α-2-glycoprotein and haptoglobin levels were significantly higher in the POD vs. control group in their proteomic cohort after hip fracture surgery, but failed to demonstrate this in their validation cohort \[[@CR32]\]. The authors concluded that their inconsistent results were due to minor differences between the two cohorts (patients in the validation group were older than the proteomic group) and also due the complexity of the pathophysiology of delirium.

### CSF S100B {#Sec23}

S100B is a calcium binding protein in the CNS mainly secreted by astrocytes under metabolic stress. Elevated levels have been implicated as a marker of acute brain damage \[[@CR53]\]. One study in both hip fracture surgery and the elective surgery showed a significant difference (POD vs. no POD, 1.38 vs. 1.08 μgramL^− 1^, *P* = 0.013) \[[@CR30]\]. However, this difference was confined to patients with pathological concentrations of phosphorylated-tau (\> 60 ng/L) - an abnormally phosphorylated protein; its presence in the CSF reflects early signs of Alzheimer's dementia \[[@CR54]\]. Another study however found no significant difference in S100B concentration between POD and non-POD groups having hip fracture surgery \[[@CR31]\]. The reason for inconsistencies were not clear, but the populations in both studies differed; with a higher proportion of nursing home and dementia patients in the positive study \[[@CR30]\].

### Neurofibrillary plaques {#Sec24}

Senile plaques composed of beta-amyloid (AB1--42) and neurofibrillary tangles (phosphorylated tau) are commonly associated with the pathological process in Alzheimer's dementia \[[@CR51]\]. The relationship of Alzheimer's disease and susceptibility of POD is not well understood, however, in one study, CSF markers for plaques and tangles were not significantly associated with POD risk in elderly hip fracture patients \[[@CR33]\].

### Leptin {#Sec25}

Leptin modulates immune response, and hypoleptinaemia can increase the production of pro-inflammatory cytokines that could result in cognitive impairment and delirium \[[@CR55]\]. Low plasma leptin was associated with POD after femoral neck fracture surgery in one study (POD vs. no POD: 4.6 vs 7.5 ngmL^− 1^, *p* \< 0.001) \[[@CR18]\].

### Hypovitaminosis {#Sec26}

Vitamin D is a steroid hormone, which acts on neuroanatomic areas that sub-serve cognition. Hypovitaminosis and its link with cognitive impairment has been described in a few studies \[[@CR56], [@CR57]\]. Theoretically, Vitamin D may have a role in protecting the brain from delirium by preventing oxidative stress in hippocampal neurons \[[@CR58]\] and promotes neuroprotection by modulating the production of choline acetyltransferase \[[@CR59]\]. One study examining serum vitamin levels in hip fracture patients showed that Vitamin D deficiency (\< 50 nmolL^− 1^) was an independent predictor of POD; mean Vitamin D levels in POD vs. no POD: 41 vs. 52 nmolL^− 1^, *p* = 0.05 \[[@CR22]\].

### Hypoalbuminemia {#Sec27}

Hypoalbuminemia is used as a marker of malnutrition and several studies have shown hypoalbuminemia as a risk factor for POD \[[@CR60], [@CR61]\]. Severe hypoalbuminaemia (\< 30 g/L) but not mild (30.1 - 35 g/L) or moderate (35.1 - 40 g/L) hypoalbuminemia was significantly associated with a two-fold higher risk of POD \[[@CR25]\].

### Brain derived neurotrophic factor (BDNF) {#Sec28}

BDNF is a protein that influences neuroplasticity and neurotransmission, learning, memory and cognition. One study showed that greater decline in BDNF levels from baseline was associated with an increased incidence of delirium in patients undergoing spine surgery; POD vs no POD 75% vs 50%, *p* = 0.03 \[[@CR24]\].

### Angiotensin III (AT III) and haemoglobin {#Sec29}

One study found that a lower AT III level (POD vs no POD, 98% vs. 106%, *p* = 0.02); and haemoglobin level pre-operatively (POD vs no POD, 13.7 vs. 14.3 g/dL, *P* = 0.02) increase the risk of developing POD in vascular surgery \[[@CR38]\].

### Imaging {#Sec30}

Integration of imaging results with information such as structural integrity or changes, vascular profile, or neurotransmitter imbalances can give rise to computational modelling of POD.

### Magnetic resonance imaging (MRI) {#Sec31}

Various techniques in MRI have been reported in predicting POD. Diffusion tensor imaging is a MRI technique that shows microstructural integrity of the brain parenchyma and has been applied to map underlying functional impairments. A significant association of premorbid diffusion tensor imaging abnormalities with delirium incidence and severity in a variety of brain regions, particularly the cerebellum was shown in one study \[[@CR34]\]. In a cohort of patients undergoing lung resection surgery, cerebral MRI showed higher proportion of white matter hyper-intensities in the POD vs. non-POD group, (mean 0.01% vs 0.005% of total intracranial volume, *P* = 0.017) \[[@CR41]\]. However, two studies involving MRI; one study on global and regional cerebral blood flow \[[@CR35]\], and another study of cortical thickness in Alzheimer's disease signature region \[[@CR36]\] showed no association with POD.

### Computed tomography imaging (CT) {#Sec32}

One study found that low total psoas area (TPA), a marker of surgical frailty was associated with an almost 3-fold increased risk of POD \[[@CR40]\].

The current evidence on pre-operative biomarkers associated with POD are summarised in Table [4](#Tab4){ref-type="table"}.

Discussion {#Sec33}
==========

Biomarkers can be useful to improve understanding of pathophysiology of POD, develop new treatment for POD, predict possible long term effects of delirium, stratify high risk patients and allow informed decision making for patients about their risks for surgery. Many biomarkers associated with dementia or hypothesized causes of post-operative delirium have been investigated.

In this review, CRP was the most promising biomarker for predicting POD. Although there is variability in CRP measurement and cut-off levels in each study, the slightly raised CRP levels that were predictive in the studies suggests that there may be an association of heightened innate inflammatory response leading to POD. There is growing evidence of raised innate inflammation associated with POD as evidenced by elevation of pre-operative inflammatory markers such as CRP, IL-6 and neopterin. One hypothesis suggests an exaggerated activation of the innate immune system results in functional changes in neurons which may lead to cognitive and behavioural changes \[[@CR62]\]. The degree of neuro-inflammation tends to increase with age, which may explain why elderly individuals are more prone to developing POD when administered anaesthesia \[[@CR63]\]. Predisposed individuals who experience stressors such as during infection or surgery may also exhibit crossing of systemic inflammatory mediators across the blood-brain barrier and activation of brain microglia, which eventually leads to neuro-inflammation and delirium \[[@CR12], [@CR64]\].

CRP is a non-specific acute phase marker in inflammation, infection and tissue damage. Although raised CRP may be non-specific to POD, the initial findings are encouraging for further research. Other biomarkers that were found to be associated with POD include BDNF, reduced cholinesterase activity, serum leptin, hypoalbuminaemia and vitamin D deficiency. However, we cannot draw any conclusions as to their roles in POD due to the limited number of studies.

The results for CSF biomarkers and imaging as predictors for POD are inconclusive. The studies that examined CSF biomarkers were for patients undergoing spinal anaesthesia, thus the patients did not require an additional lumbar puncture to obtain CSF. The risks and invasiveness of obtaining CSF (if a patient was not already undergoing spinal anaesthesia) and costs applied to imaging may limit their practicality in clinical practice.

Strengths and limitations {#Sec34}
-------------------------

The strengths of this review include the comprehensive literature search using different search terms from several large databases and the total number of patients included from geographically diverse areas.

The limitations of the review are that most studies were relatively small and some biomarkers were only studied in one study, hence limiting quantitative assessment and meta-analysis of results. Some studies used the same cohort of patients to test different biomarkers. Secondly, we restricted our search only to English language articles. Most studies were conducted in orthopaedic surgery; therefore, the results may not be generalised to other types of surgery. Another limitation is that some studies included patients with pre-existing cognitive impairment or dementia \[[@CR7], [@CR9], [@CR11], [@CR14], [@CR26], [@CR27], [@CR31]--[@CR33]\]. However, no statistical difference were found in pre-operative cognitive scores between control and POD groups in all the studies. Some studies did not perform multivariate analysis which may not account fully for potential confounders \[[@CR7], [@CR9], [@CR11], [@CR12], [@CR14], [@CR16], [@CR17], [@CR21], [@CR23], [@CR27], [@CR30]--[@CR32], [@CR34], [@CR41]\]. The timing of POD assessment also varied, and no study mentioned if they included PACU delirium. However, whether delirium in PACU is considered POD is subject to debate, and although its assessment is different (CAM-ICU has a higher specificity than sensitivity for delirium when used in PACU) \[[@CR2]\], the relatively high incidence of PACU delirium (16.4%) \[[@CR3]\] may be relevant in accounting for the accurate incidence of POD.

Therefore, further research should incorporate a variety of surgical procedures, align timing of POD assessment including PACU delirium, using multivariate models and adjust for confounding factors.

Conclusions {#Sec35}
===========

The current literature regarding pre-operative biochemical markers and imaging tests for predicting post-operative delirium is still in its infancy. There is some evidence that serum CRP levels \> 3 mgL^− 1^ may predict a high risk of developing POD, and incorporating it along with other patient and surgical predisposing factors of POD may increase the identification of high risk patients. However, this should be interpreted with caution due to heterogeneity of predictive test values and the small sample size of the studies precluded sensitivity analysis to demonstrate significant association. On the other hand, delineating specific biomarkers may also lead to forming composite markers (combining 2 or more biomarkers) which could increase predictive value. From a clinical perspective, utilising predictive biomarkers may allow better clinical decision making and management of high risk patients to specific recovery units.
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